According to a report today on Xconomy.com, the U.S. Food & Drug Administration has approved the Progensa® PCA3 test developed by Gen-Probe.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, PCA3, risk, test | 4 Comments »
FDA approves Gen-Probe PCA3 test (Progensa)
Posted on February 15, 2012 by Sitemaster
Occurrence of infections and hospitalizations in men having prostate biopsy (in Europe)
Posted on February 7, 2012 by Sitemaster
There has been increased discussion in the past couple of years related to the risk of infection in men undergoing prostate biopsy after initial testing for risk of prostate cancer (based on results of PSA test data and/or a digital rectal examination).
Filed under: Diagnosis, Risk | Tagged: biopsy, hospitalization, infection, risk | 7 Comments »
Biopsy in D minor by Johann Sebastian you know who
Posted on January 13, 2012 by Sitemaster
A group of medical students and fellows at Duke University have shown that if you distract patients’ attention while they are having a prostate biopsy it can (at least to some extent) reduce the likelihood of patient reports of pain and anxiety associated with the procedure.
Filed under: Diagnosis | Tagged: anxiety, Bach, biopsy, Brandenberg, pain | 10 Comments »
African-American men significantly underestimate their risk of a positive prostate biopsy
Posted on December 20, 2011 by Sitemaster
According to new data from a study at the University of Chicago, African-American males scheduled for a prostate biopsy are at greater risk for a positive diagnosis of cancer than white males and they also significantly underestimate their probability of a positive biopsy result.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: belief, biopsy, ethnicity, outcome, race, risk | Leave a Comment »
What happens next after a baseline PSA test?
Posted on October 26, 2011 by Sitemaster
According to data from a prospective study of prostate cancer outcomes conducted by researchers at the Mayo Clinic, the PSA test is “valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer.”
Filed under: Diagnosis, Management, Risk | Tagged: benefit, biopsy, PSA, risk | 3 Comments »
Another investigational test may refine data on need for prostate biopsy
Posted on October 23, 2011 by Sitemaster
A newly published paper in the Journal of Urology describes a multi-center, prospective study of the potential of the investigational, urine-based, ProCaM™ assay as a test to offer improved evaluation of the need for prostate biopsy among men with an initial total serum PSA level between 2 and 10 ng/ml.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, epigenetic, ProCaM, PSA, risk, test | 7 Comments »
New data on risks of prostate biopsy and prostate cancer diagnosis, follow-up
Posted on September 23, 2011 by Sitemaster
According to a new study among Medicare beneficiaries in the USA, researchers have found that 6.9 percent of men having a prostate biopsy are hospitalized within 30 days of the biopsy compared to 2.7 percent of a control group of men who did not have a prostate biopsy.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, complications, hospitalization, risk | 1 Comment »
Canadian company claims new test is 600% more accurate than free PSA test
Posted on September 8, 2011 by Sitemaster
According to a media release issued by the Canadian company BioCurex earlier today, its new RECAF™ test “outperformed the established free-PSA test by approximately 600% in its ability to prevent unnecessary prostate biopsies.”
Filed under: Diagnosis, Risk | Tagged: BioCurex, biopsy, α-fetoprotein, RECAF, test | Leave a Comment »
Should all low-risk prostate cancer patients be re-biopsied prior to implementation of active surveillance?
Posted on August 30, 2011 by Sitemaster
Centers apply a variety of inclusion criteria in evaluating the eligibility of patients for management using active surveillance (AS) protocols. The applicability of an immediate, transrectal ultrasound (TRUS)-guided re-biopsy is recommended by a number of centers, but there is no consensus about the need for re-biopsy at this time.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, biopsy, eligibility, repeat | 4 Comments »
New urine-based test may be able to eliminate need for biopsy in many patients
Posted on August 11, 2011 by Sitemaster
A new report giving preliminary data on the clinical performance of novel, urine-based prostate cancer assay uses a method known as prostate-specific antigen/solvent interaction analysis (PSA/SIA) to detect the ratios of different types of PSA (PSA “isoforms”) in the urine of men beleived to be at risk for prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, Diagnosis, isoform, PSA, PSA/SIA, risk, solvent, urine | 2 Comments »
“New” urine test combines data from PCA3 and gene fusion to predict prostate cancer risk
Posted on August 4, 2011 by Sitemaster
There is a lot of media coverage from late yesterday about a “new” urine test for diagnosis of prostate cancer that is being developed by the University of Michigan in combination with San Diego-based Gen-Probe. Whether the actual value of the test can live up to the media coverage is going to take a while [...]
Filed under: Diagnosis, Risk | Tagged: biopsy, PCA3, risk, test, TMPRSS2:ERG | 1 Comment »
Color Doppler ultrasound in the biopsy-based diagnosis of prostate cancer
Posted on August 1, 2011 by Sitemaster
A new report from an Italian clinical research team, and based on a randomized clinical trial of 300 patients, suggests that color Doppler ultrasound offers no significant benefit over standard “gray-scale” ultrasound in the biopsy-based diagnosis of prostate cancer — which is not going to please the advocates of color Doppler ultrasonography.
Filed under: Diagnosis, Risk | Tagged: biopsy, color Döppler, Diagnosis, guidance, SonoVue, transrectal, ultrasound | 4 Comments »
Clinical and pathologic staging of localized prostate cancer: an update
Posted on July 25, 2011 by Sitemaster
A new review by Epstein, currently available on line in the Journal of Urology, provides a detailed analysis of the clinical significance of various factors in determining prognostic risk for newly diagnosed and recently treated patients with localized prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinical, core, pathologic, prognosis, quantification, stage, T2, tumor, volume | 10 Comments »
Prostate cancer risk calculators and the decision to have a prostate biopsy
Posted on July 15, 2011 by Sitemaster
A new paper in the Journal of Clinical Oncology provides some interesting insights into the relative merits of the two major prostate cancer risk calculators widely used today in North America: the original PCPT-based risk calculator (PRC) and the Sunnybrook risk calculator (SRC).
Filed under: Diagnosis, Risk | Tagged: biopsy, calculator, prognosis, Prostate Cancer Prevention Trial, risk, Sunnybrook | Leave a Comment »
Low-risk prostate cancer, active surveillance, and perineural invasion
Posted on July 7, 2011 by Sitemaster
A previously unanswered question is whether a finding of perineural invasion in the biopsy cores of men who otherwise meet all relevant criteria for management by active surveillance does or does not actually increase risk for progressive forms of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: active surveillance, biopsy, perineural invasion, risk | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
